Abstract
Background Major Depressive Disorder (MDD) is a prevalent mental health condition with significant public health implications. Early detection is crucial for effective intervention, yet current diagnostic methods often fail to identify MDD in its early stages.
Objective This study aimed to develop and validate machine learning models for the early detection of MDD using functional Magnetic Resonance Imaging (fMRI) data.
Methods We utilized fMRI data from 1,200 participants (600 with early-stage MDD and 600 healthy controls) across three public datasets. Four machine learning models (Support Vector Machine (SVM), Random Forest (RF), Gradient Boosting Machine (GBM), and Deep Neural Network (DNN)) were developed and compared. Models were evaluated using accuracy, sensitivity, specificity, area under the receiver operating characteristic curve (AUC-ROC), and F1 score.
Results The DNN model demonstrated superior performance, achieving 89% accuracy (95% CI: 0.86-0.92) and an AUC-ROC of 0.95 (95% CI: 0.93-0.97) in detecting early-stage MDD. Key predictive features included altered functional connectivity between the dorsolateral prefrontal cortex, anterior cingulate cortex, and limbic regions. The model showed good generalizability across different datasets and identified 78% (95% CI: 71%-85%) of individuals who developed MDD within a 2-year follow-up period.
Conclusions Our AI-driven approach demonstrates promising potential for early MDD detection, outperforming traditional diagnostic methods. This study highlights the utility of machine learning in analyzing complex neuroimaging data for psychiatric applications. Future research should focus on prospective clinical trials and the integration of multimodal data to enhance the clinical applicability of this approach further.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly availably human data originally located at OpenfMRI Depression Dataset, REST-meta-MDD Dataset, EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Dataset
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
